NCT06429722 - To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

April 9, 2025

Study Completion Date

May 30, 2025

Conditions

Major Depressive Episode Associated With Bipolar II Disorder

Interventions

DRUG

NMRA-335140 80 mg

Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.

DRUG

Placebo

Placebo will be administered orally

Trial Locations (21)

11229

Neumora Investigator Site, Brooklyn

30060

Neumora Investigator Site, Marietta

31405

Neumora Investigator Site, Savannah

32607

Neumora Investigator Site, Gainesville

32751

Neumora Investigator Site, Maitland

33016

Neumora Investigator Site, Miami Lakes

33122

Neumora Investigator Site, Miami

33161

Neumora Investigator Site, Lauderhill

39232

Neumora Investigator Site, Flowood

72211

Neumora Investigator Site, Little Rock

77030

Neumora Investigator Site, Houston

85012

Neumora Investigator Site, Phoenix

90504

Neumora Investigator Site, Torrance

90807

Neumora Investigator Site, Long Beach

92845

Neumora Investigator Site, Garden Grove

95124

Neumora Investigator Site, San Jose

98007

Neumora Investigator Site, Bellevue

02472

Neumora Investigator Site, Watertown

08053

Neumora Investigator Site, Marlton

08540

Neumora Investigator Site, Princeton

08755

Neumora Investigator Site, Toms River